• 1. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 2. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 3. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003

MY33-3 Hydrochloride: A Promising Compound in the Field of Medicinal Chemistry

MY33-3 hydrochloride (CAS No. 2204280-42-0) is a novel compound that has garnered significant attention in the field of medicinal chemistry due to its unique properties and potential therapeutic applications. This compound, a hydrochloride salt, has been extensively studied for its biological activities and pharmacological properties, making it a focal point in various research areas, including cancer therapy, neurodegenerative diseases, and inflammatory disorders.

The chemical structure of MY33-3 hydrochloride is characterized by its complex molecular framework, which includes a central aromatic core and several functional groups that contribute to its bioactivity. The hydrochloride form of the compound enhances its solubility and stability, making it more suitable for in vitro and in vivo studies. Recent research has highlighted the compound's ability to selectively target specific cellular pathways, which is crucial for its therapeutic potential.

In the context of cancer therapy, MY33-3 hydrochloride has shown promising results in inhibiting the proliferation of various cancer cell lines. Studies have demonstrated that the compound can induce apoptosis (programmed cell death) in cancer cells while sparing normal cells. This selective cytotoxicity is attributed to its ability to modulate key signaling pathways involved in cell survival and proliferation. For instance, MY33-3 hydrochloride has been shown to inhibit the activation of the PI3K/AKT/mTOR pathway, which is frequently dysregulated in many types of cancer.

Beyond cancer, MY33-3 hydrochloride has also been investigated for its potential in treating neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Preclinical studies have indicated that the compound can reduce neuroinflammation and protect neurons from oxidative stress. These effects are thought to be mediated by its ability to modulate microglial activation and inhibit the production of pro-inflammatory cytokines. Additionally, MY33-3 hydrochloride has been shown to enhance autophagy, a cellular process that helps remove damaged proteins and organelles, thereby promoting neuronal health.

Inflammatory disorders represent another area where MY33-3 hydrochloride shows promise. Chronic inflammation is a hallmark of many diseases, including rheumatoid arthritis and inflammatory bowel disease. Research has demonstrated that MY33-3 hydrochloride can effectively reduce inflammation by inhibiting the production of pro-inflammatory mediators such as TNF-α and IL-6. Furthermore, the compound has been shown to downregulate the expression of adhesion molecules on endothelial cells, thereby reducing leukocyte infiltration into inflamed tissues.

The pharmacokinetic properties of MY33-3 hydrochloride have also been extensively studied to optimize its therapeutic potential. Preclinical data indicate that the compound exhibits favorable oral bioavailability and a reasonable half-life, making it suitable for chronic administration. Additionally, MY33-3 hydrochloride has shown low toxicity in animal models, suggesting a favorable safety profile for further clinical development.

Clinical trials are currently underway to evaluate the safety and efficacy of MY33-3 hydrochloride in human subjects. Early-phase trials have reported promising results, with patients showing significant improvements in disease symptoms and biomarkers. These findings have paved the way for larger-scale trials to further validate the therapeutic potential of this compound.

In conclusion, MY33-3 hydrochloride (CAS No. 2204280-42-0) is a promising compound with a wide range of potential applications in medicinal chemistry. Its unique chemical structure and biological activities make it an attractive candidate for further research and development. As ongoing studies continue to uncover new insights into its mechanisms of action and therapeutic benefits, MY33-3 hydrochloride holds significant promise for improving patient outcomes in various disease conditions.

• 128273-56-3(4-(Trifluoromethylthio)benzylamine)
• 893586-36-2(N-(4-(Methylthio)benzyl)ethanamine)
• 1221722-62-8(Benzenemethanamine, 4-[(difluoromethyl)thio]-N-methyl-)
• 1049773-81-0(N-[4-(methylthio)benzyl]ethanamine hydrochloride)
• 89807-48-7(Benzenemethanaminium, N,N,N-tributyl-4-[(trifluoromethyl)thio]-,chloride)
• 127842-66-4({4-(trifluoromethyl)sulfanylphenyl}methanamine hydrochloride)
• 2204280-41-9(Benzenemethanamine, 4-[(trifluoromethyl)thio]-N-[[4-[(trifluoromethyl)thio]phenyl]methyl]-)
• 234450-33-0({3-(trifluoromethyl)sulfanylphenyl}methanamine)
• 2701705-46-4(1-(4-((Trifluoromethyl)thio)phenyl)ethan-1-amine hydrochloride)
• 1800240-39-4((R)-1-(4-((Trifluoromethyl)thio)phenyl)ethanamine hydrochloride)